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Key Points
• Risk-adapted therapy and
broad use of HSCT resulted in
a significant improvement in
outcome.
• AUTO- or ALLO-HSCT in
high-risk patients resulted
in a cumulative incidence
of leukemia relapse
superimposable to that of SR.
We evaluated the outcome of 482 children with acute myeloid leukemia (AML) enrolled in
the Associazione Italiana di Ematologia e Oncologia Pediatrica AML 2002/01 trial.
Treatment was stratified according to risk group; hematopoietic stem cell transplantation
(HSCT) was used in high-risk (HR) children. Patients with core binding factor leukemia
achieving complete remission (CR) after the first induction course were considered
standard risk (SR; 99 patients), whereas the others (n 5 383) were assigned to the HR
group. Allogeneic (ALLO) or autologous (AUTO) HSCTwas employed, respectively, in 141
and 102 HR patients after consolidation therapy. CR, early death, and induction failure
rates were 87%, 3%, and 10%, respectively. Relapse occurred in 24% of patients achieving
CR. The 8-year overall survival (OS), event-free survival (EFS), and disease-free survival
(DFS) were 68%, 55%, and 63%, respectively. OS, EFS, and DFS for SR and HR patients
were 83%, 63%, and 66% and 64%, 53%, and 62%. DFS was 63% and 73% for HR patients
given AUTO-HSCT and ALLO-HSCT, respectively. In multivariate analysis, risk group,
white blood cell >100 3 109/L at diagnosis, and monosomal karyotype predicted poorer EFS. Risk-oriented treatment and broad
use of HSCT result in a long-term EFS comparing favorably with previously published studies on childhood AML. (Blood. 2013;
122(2):170-178)
Introduction
The prognosis of childhood acute myeloid leukemia (AML) has sig-
nificantly improved over the last 2 decades.1,2 In particular, the most
recent and successful reports showed a probability of event-free
survival (EFS) ranging between 40% and 60%.3-11 This improve-
ment was largely due to (1) significant progress in stratification of
patients, with a consequent risk-directed therapy; (2) optimization
in induction and postremission treatment strategy, including the
use of repeated courses of high-dose cytarabine (HD Ara-C); (3)
better supportive therapy; and (4) broad use of allogeneic (ALLO)
hematopoietic stem cell transplantation (HSCT) in high-risk (HR)
patients.3 In this regard, in the past, randomized trials showed that
ALLO-HSCT from an HLA-identical sibling is the postremission
treatment able to offer the best chance of sustained remission.12-14
The efficacy of ALLO-HSCT from an HLA-matched sibling has
been recently confirmed in the subsets of patients with intermediate/
HR features.15 Despite these data, in the last years, and in view of an
improved probability for relapsed patients to be rescued by salvage
therapy, the use of ALLO-HSCT in children with AML in first
complete remission (CR1) has been questioned by some groups.16,17
The role of autologous (AUTO) HSCT as postremission therapy for
AML is even more controversial, and some studies have suggested an
advantage over chemotherapy in terms of prevention of leukemia
relapse,18 which, after the introduction of HD Ara-C in consolidation
therapy, has not been confirmed12-14 or was offset by an increased risk
of transplantation-related mortality (TRM).19
Since December 2002, children without Down syndrome and
with newly diagnosed, de novo AML other than promyelocytic
leukemia (APL) were treated at Italian centers affiliated with
Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)
according to the AML 2002/01 protocol, the latest of 5 consecutive
studies on childhood AML (LAM-82, LAM-87, LAM-87M, LAM-
92, and AML 2002/01) conducted in Italy since 1982.4 The primary
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objective chosen when the study was designed was that of obtaining
a 5-year EFS .50%. In order to reach this goal, in view of the
evidence available at that time on factors influencing outcome, we
stratified children according to cytogenetic/molecular findings and
response to the first course of induction therapy. In particular,
assigned to the standard risk (SR) treatment were children with either
AML1-ETO fusion transcript or anomalies of core binding factor b
(CBF-b) and in morphologic CR after the first of 2 induction courses.
In all patients, consolidation therapy included courses containing HD
Ara-C. It was also decided that patients allocated to the HR group
were broadly offered either AUTO- or ALLO-HSCT, depending on
the availability of an HLA-identical sibling.
In this report, we describe the results obtained in children
enrolled in the AML 2002/01 protocol.
Patients and methods
Eligibility
The entry criteria for the AIEOP AML 2002/01 study included (1) newly
diagnosed de novo AML other than APL; (2) age ranging from 0 to 18 years;
and (3) written informed consent from parents or legal guardians in accor-
dance with the Declaration of Helsinki. Other eligibility criteria included
serum bilirubin <33 upper limit of normal (ULN) for age, aspartate amino-
transferase and alanine aminotransferase <53 ULN, and serum creatinine
<23 ULN for age. Patients with a previous myelodysplastic phase or who
had received previous treatment with either cytotoxic agents or steroids during
the 2 weeks preceding diagnosis were excluded. The study was approved by
the local ethics committees of each participating institution.
Diagnostic procedure
The initial diagnosis of AML with definition of subtype was established
according to the French-American-British (FAB) and World Health Orga-
nization classification criteria. Bone marrow (BM) smears obtained at time of
diagnosis were centrally reviewed at the Laboratory of Pediatric Hematology
in Padua. All samples at diagnosis were analyzed for the presence of t(8;21),
inv(16), t(16;16), t(15;17), and t(11q23)/mixed-lineage leukemia (MLL) and
the related molecular transcripts, namely AML-ETO1, CBF-b abnormalities,
promyelocytic leukemia-retinoic acid receptor a, and MLL rearrangements.
Molecular analyses for internal tandem duplication of FLT-3 mutation (FLT3-
ITD) and activating loop mutations of the same gene were also performed. The
diagnosis of both FAB M0 and M7 subtypes was always confirmed by
immunophenotype.
Morphologic CR status and diagnosis of relapse were centrally reviewed.
Definitions
CRwas defined as,5%morphologically evident leukemic blasts in BMwith
normal hematopoiesis, no leukemia cells in peripheral blood or anywhere else,
and signs of normal blood cell production (platelets .50 3 109/L without
support, neutrophils . 1.0 3 109/L) after induction phase. Early death (ED)
was defined as a fatal event occurring within the first 6 weeks from diagnosis.
Patients who did not achieve CR and who survived after the first course
of treatment were divided in 2 groups: (1) partial responders (PR) were
patients with percentage of BM leukemia blasts between 5% and 25% at the
end of the first course of induction therapy; and (2) nonresponders (NR) were
patients with percentage of BM leukemia blasts .25% at the end of the first
course of induction therapy or patients with BM leukemia blasts .5% after
the second induction course.
Central nervous system (CNS) involvement was defined as.5 leukocytes
per mL of CSF and presence of leukemia cells on cytospin preparations or
cranial nerve involvement.
Treatment design
Details on treatment are reported in Figure 1 and Table 1. Patients enrolled in
the AIEOP AML 2002/01 study were assigned to either the SR or HR group.
As mentioned above, patients belonging to the former group had isolated
anomalies of CBF-b and were in morphologic CR after the first induction
course; the remaining children were assigned to the HR group. All patients,
irrespective of the risk group, were given 2 courses of induction chemo-
therapy, including idarubicin, cytarabine, and etoposide (ICE; see Table 1 for
details). BM evaluation to document response to the first induction course was
on day 121. The second induction course for patients achieving CR was
scheduled to start at time of hematologic recovery and preferably no later than
28 days after the beginning of the first course, in the absence of complications
precluding cytotoxic treatment. PR and NR patients started either the second
cycle of induction or salvage therapy, respectively, at time of evidence of
leukemia persistence. Children in CR after the second induction course recei-
ved 2 consolidation courses, includingHDAra-C, combined with etoposide in
the first course (AVE; Table 1) and mitoxantrone in the second course (HAM;
Table 1). At the end of this treatment, SR patients still in CR1 were given
a further course of HD Ara-C (Table 1), while HR patients had the indication
to receive either ALLO- or AUTO-HSCT, depending on the availability of an
Figure 1. Schematic representation of the induction and consolidation courses employed for treating patients enrolled in the AIEOP AML 2002/01 trial. AVE, HD
Ara-C and etoposide; CONS, consolidation; HAM, HD Ara-C and mitoxantrone; MFD, matched family donor.
BLOOD, 11 JULY 2013 x VOLUME 122, NUMBER 2 RESULTS OF THE AIEOP AML 2002/01 TRIAL 171
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/122/2/170/1371391/170.pdf by U
N
IVER
SITA STU
D
I D
I TO
R
IN
O
 user on 10 April 2020
HLA-identical family donor. Among HR patients, those,1 year of age, with
AML-M7, or not in CR at the end of first ICE, or with a complex karyotype
were considered at particularly HR of recurrence and, thus, eligible to be
transplanted from unrelated donors (UD). After 2006, all patients with FLT3-
ITD in CR1 were also offered an UD allograft. NR patients were eligible for
salvage therapy.
Conditioning regimen combined busulfan (16 mg/kg), cyclophosphamide
(120 mg/kg), and melphalan (L-PAM; 140 mg/m2) for both AUTO- and
ALLO-HSCT.20 Busulfan dosage was adjusted based on the pharmacokinetic
study performed following the first administration in order to maintain
a steady-state concentration between 600 and 900 ng/mL. Patients given
AUTO-HSCT were recommended to have in vitro marrow purging with
mafosfamide.21
Statistical analysis
The analysis used June 30, 2012, as the reference date.
Overall survival (OS) was calculated from date of diagnosis to time of
death due to any cause or time of last contact. EFS was calculated from date of
diagnosis to last follow-up or first event (failure to achieve CR, relapse, second
malignancy, or death due to any cause, whichever occurred first). Patients who
did not attain CR after 2 induction cycles were considered failures at time of
remission evaluation. Disease-free survival (DFS) was calculated from the
date of remission for both SR and HR patients reaching CR1 or, for the HR
children given transplantation, from date of HSCT to last follow-up or first
event (relapse, second malignancy, or death due to any cause, whichever
occurred first).
Probabilities of OS, EFS, and DFS were estimated using the Kaplan-
Meier method. Cumulative incidence (CI) of relapse and death in continuous
CR (CCR) were constructed using the method of Kalbfleisch in order to
adjust the analysis for competing risks. Death in remission was treated as
a competing event to calculate CI of relapse, while relapse was considered
the competing event for death in CCR. The significance of differences
among the OS, EFS, and DFS curves was estimated by the log-rank test
(Mantel-Cox), while Gray’s test was used to assess differences between CI of
relapse and death in CCR. All variables having a P value , .05 in univariate
analysis were included in a multivariate analysis on EFS using the Cox
proportional regression model. Computations were performed using SAS
(SAS Institute, Cary, NC).
Table 1. AIOP LAM 2002 chemotherapy schedule
Phase Week
Administration
route Doses Days
Remission induction
(ICE 32)
Idarubicin 1, 4 IV 10 mg/m2 1, 2, 3
Etoposide 1, 4 IV 100 mg/m2 1, 2, 3, 4, 5
Cytarabine 1, 4 IV (24 h) 200 mg/m2 1, 2, 3, 4, 5, 6,
7
IT therapy 1, 4
Cytarabine 1, 4 IT Depending
on age*
1
Methotrexate (only
for CNS disease)
1, 4 IT Depending
on age*
1, 4, 7, 10, 14
of first cycle
Methylprednisolone
(only for CNS
disease)
1, 4 IT Depending
on age*
1, 4, 7, 10, 14
of first cycle
Consolidation 1 (AVE)
Etoposide 8 IV 125 mg/m2 2, 3, 4, 5
Cytarabine 8 IV 3 g/m2 bid 1, 2, 3
IT therapy
Cytarabine 8 IT Depending
on age*
6
Consolidation 2 (HAM)
Cytarabine 11 IV 3 g/m2 bid 1, 2, 3
Mitoxantrone 11 IV 10 mg/m2 3, 4
IT therapy
Cytarabine 11 IT Depending
on age*
6
Consolidation 3 (HD
Ara-C) (only for SR)
Cytarabine 14 IV 3 g/m2 bid 1, 2, 3
IT therapy
Cytarabine 14 IT Depending
on age*
6
CNS disease was considered as presence of .5 leukemia blasts in the
cerebrospinal fluid, or nerve palsy or CNS involvement, at either nuclear magnetic
resonance or at computed tomography scan.
AVE, high-dose cytarabine; bid, twice daily; HAM, HD Ara-C and mitoxantrone;
IT, intrathecal; IV, intravenous.
*Children ,1 year received 20 mg cytarabine, while those aged between 1 and
2, or 2 and 3, or .3 years were given 30, 50, and 70 mg, respectively.
Table 2. Patient characteristics of the AIEOP LAM 2002/01 protocol
Characteristic n %
Number of evaluable patients 482 100
Gender
Male 262 52
Female 220 48
Age
,1 y 63 13
1-2 y 52 10
2-10 y 181 38
.10 y 186 39
WBC count (3109/L)
,10 171 35
10-99 236 49
.100 75 16
CNS leukemia (yes) 40 8
FAB subtype
M0 34 7
M1 88 18
M2 91 19
M4 40 8
M4 Eo 43 9
M5 117 24
M6 5 1
M7 44 9
Unclassifiable/not known 20 4
Cytogenetics
Patients with available cytogenetic data 418
Favorable cytogenetics 99 24
t(8;21) 72 17
t(16;16) 1 0
inv 16 26 6
Translocation t(9;11) 19 5
Other 11q23 abnormalities 46 11
Complex karyotype 27 6
Normal 166 39
Other abnormalities 61 15
FLT3 aberrations
Patients tested for FLT3 aberrations 384
ITD 42 11
Activating loop mutations (D835/I836) 10 3
Wild-type 332 86
Other molecular aberrations
Patients tested 244
NPM mutations 14 6
CEBPa mutations 18 7
Risk groups
SR 99 20
HR 383 80
CEBPa, CCAAT/enhancer binding protein; ITD, internal tandem duplication;
NPM, nucleophosmin.
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Results
Between December 2002 and June 2011, 504 children with de novo
AML other than APL were enrolled in the study; 482 of them are
evaluable. Twenty-two were excluded due to death before initiation
of therapy (n 5 3), previous treatment with steroids (n 5 7) or with
cytotoxic drugs (n 5 5), and previous diagnosis of myelodysplastic
syndrome (n5 7). Children were diagnosed and treated at 29 centers
affiliated with the AIEOP network; the number of patients aged,14
years treated per year was consistent with the expected number of
new cases in Italy.22 Each center treated a number of patients ranging
from 2 to 69 (median value: 9). Patient characteristics are shown in
Table 2, while patient flowchart is depicted in Figure 2.
Overall, 87% of 482 patients achieved CR after induction, the
early death and induction failure rates being 3% and 10%, respec-
tively. In detail, 13 children died during induction courses and 48
were NR at the end of induction therapy (see also Figure 2). Among
these 48 patients, 16 died due to either disease progression or
treatment-related complications, while 32 (67%) subsequently
reached CR after salvage therapy.
After the first course of induction therapy, 99 children were
assigned to SR (20% of the whole population) as they had anomalies
of CBF-b and were in morphological CR (Table 3). Notably, none
of the children with CBF-b anomalies were resistant to the first
induction course; thus, the CR rate of these children was 100%.
Three SR patients died between the first and second ICE course, and
thus the number of SR patients at the end of the cycles of induction
therapy was 96 (23% of those being in CR after induction therapy).
The remaining 325 children (77%) belonged to the HR group (see
also Figure 2). The CR rate of children other than those with CBF-b
anomalies was 85%. The median time elapsing between the begin-
ning of the first and second course of induction therapy was 28 days
(range 21-66 days).
Thirty-seven patients died in CR after induction therapy; 33 and 4
out of these 37 children had been assigned to the HR and SR groups,
respectively (P5 .07). Of these 37 patients, 16 died after HSCT. The
causes of death for the 21 patients who died in CR without or before
having received HSCT were infections in 19 cases (6 of which were
attributable to an invasive fungal infection) and cerebral hemorrhage
in the remaining 2 children. The CI of death in CCR was 10%
(standard error [SE] 1.7). Adolescents had a greater risk of death in
CCR as compared with children aged ,14 years (23% vs 6% in
younger patients, P5 .02). In detail, among the 14 adolescents who
died in CR, 9 experienced fatal infections, 2 veno-occlusive disease
after HSCT, 2 chronic graft-versus-host disease (GVHD), and 1
cerebral hemorrhage. Five adolescents died after HSCT.
Relapse occurred in 103 children (24%) who had achieved CR;
24 and 79 relapses occurred in SR andHR children, respectively. The
median time between diagnosis and recurrence was 12.4 months
(range 1.2-54.5 months). Four SR and 28 HR children relapsed while
receiving consolidation therapy (see also Figure 2). Relapse involved
BM only in 87 cases, BM and other extramedullary sites in 12 cases,
and extramedullary sites in 4 cases only. The CI of relapse was 27%
for both SR and HR patients (SE 4.7 and 2.8, respectively). Among
the 24 SR patients who relapsed, 7 died of either disease progression
(4 children) or toxicity during salvage treatment (3 children), while
17 patients are alive and disease-free in second CR. Of the 79 HR
children experiencing leukemia recurrence, 66 died of either disease
progression (50 children) or toxicity during salvage treatment (16
children), while 13 patients are alive and disease-free in second CR
(see also Table 3).
With a median follow-up of 57 months (range 12-130 months),
the 8-year probability of OS, EFS, and DFS for the whole cohort was
68% (SE 2.4), 55% (SE 2.6), and 63% (SE 2.7), respectively
(Figure 3). OS, EFS, and DFSwere 83% (SE 4.6), 63% (SE 5.6), and
66% (SE 5.7) in the SR group; these values were 64% (SE 2.8), 53%
(SE 2.9), and 62% (SE 3.1) in the HR group (Figure 4). Both the
probability of OS and EFS were better for SR patients, with P values
of .0003 and .02, respectively; by contrast, the probability of DFS
did not differ between the 2 groups of risk. All patients with
nucleophosmin and CCAAT/enhancer binding protein a were as-
signed to the HR group; their probability of EFS was 64% and 60%,
respectively (see also Table 4).
Notably, the 8-year OS of the 48 NR patients was 30% (SE
7.6). Of them, 27 were given an allograft, either in CR or with
persistent disease, from an HLA-identical sibling or an alternative
donor.
Figure 2. Flowchart of patients enrolled in the 2000/01
AML protocol.
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Considering variables potentially influencing outcome (see
Table 4 for details), we found that patients with white blood cell
(WBC) count at diagnosis .100 3 109/L had a worse outcome as
compared with the others, the EFS being 37% (SE 5.7) and 58%
(SE 2.8), respectively (P , .05). The 8-year EFS of the 27 patients
with complex karyotype (defined as >3 abnormalities, either
numerical or structural) was 40% (SE 9.6) as compared with 56%
(SE 2.6) in the other patients (P, .05). The EFS of patients carrying
(n 5 10) or not (n 5 472) a monosomal karyotype, defined as the
presence of isolated 27 and 25, was 20% (SE 12.6) and 53%
(SE 2.9), respectively (P5 .0002). Noteworthy, FLT3-ITD did not
influence the probability of EFS (see also Table 3). In multivariate
analysis for EFS, risk group (either SR or HR), WBC count at
diagnosis.1003 109/L, and monosomal karyotype predicted poor
patient outcome (with P values of .001, .001, and .049 and hazard
ratios of 1.95, 3.37, and 1.52, respectively).
As far as the outcome of the 243 patients given transplantation in
CR1 is concerned, the 8-year DFS, calculated from the date of HSCT,
for the 102 patients given AUTO-HSCT was 63% (SE 4.9); it was
73% (SE 4.0) for the 141 patients given ALLO-HSCT (P value not
significant). Among this latter group, DFS was 71% (SE 6.3) and
79% (SE 6.2) for the 66 and 75 patients transplanted from a relative or
an UD, respectively. Sixteen patients died after HSCT; causes of
death were acute GVHD (n 5 3), chronic GVHD (n 5 4), veno-
occlusive disease (n 5 4), and infection (n 5 5). The 8-year CI of
TRM after either AUTO- or ALLO-HSCT from an HLA-compatible
sibling or an UDwas comparable (7% in both cohorts). The 8-year CI
of relapse after AUTO- and ALLO-HSCT was 28% (SE 4.5) and
17% (SE 3.3), respectively (P 5 .043).
Thirty-seven HR patients (11% of the whole HR population)
received neither AUTO- nor ALLO-HSCT at the end of consolida-
tion courses (Figure 2) due to parent refusal (21 patients), physician
decision (10 patients), or complications occurring during chemo-
therapy treatment and precluding transplantation (7 patients). These
37 HR patients did not differ from the other HR children and their
OS and DFS probability, calculated from the end of consolidation
chemotherapy, was 47% (SE 7.1) and 43% (SE 7.3), respectively. In
comparison with HR patients given ALLO- and AUTO-HSCT, after
adjusting for waiting time to transplantation (39 days, range 31-58
days), both DFS and OS of the 37 nontransplanted HR patients were
lower (P 5 .033 and P 5 .041, respectively).
Discussion
The 8-year OS and EFS probabilities of 68% and 55%, respectively,
achieved in this multicenter study of risk-adapted therapy, based on
genetic features and response to induction therapy, are better than
those reported in previous AIEOP studies.4 This improvement can be
attributed to a lower risk of both treatment-related death and disease
recurrence. In particular, the ED rate (3%) of the AML 2002/01
protocol compares favorably with those reported in the LAM-92,
LAM-87M, LAM-87, and LAM-82 studies (6%, 14%, 5%, and 9%,
respectively).4 Our ED rate is similar to that reported by the BFM5
and MRC groups6,23 but worse than those reported by a monoinstitu-
tional study at St. Jude7 and by the NOPHO24 and Japanese pediatric
groups.8 Also, the incidence of death in CCR of our study (10%) was
comparable to that recently reported by Rubnitz et al7 (9%). We
found that both HR patients and adolescents were exposed to a
greater risk of experiencing fatal toxicities. This observation suggests
Table 3. Characteristics of SR and HR patients
SR patients
n (%)
HR patients
n (%) P value
Number of evaluable patients 99 (100) 383 (100)
Gender
Male 59 (60) 203 (53) .6
Female 40 (40) 180 (47) .6
Age
,1 y 2 (2) 61 (16) .01
1-2 y 7 (7) 45 (12) .1
2-10 y 43 (43) 138 (36) .5
.10 y 47 (47) 139 (36) .3
WBC count (3109/L)
,10 31 (31) 140 (36) .6
10-99 57 (58) 179 (47) .3
.100 11 (11) 64 (17) .3
CNS leukemia (yes) 4 (4) 36 (9) .2
FAB subtype
M0 0 (0) 34 (9) <.01
M1 5 (5) 83 (22) .02
M2 60 (61) 31 (8) <.01
M4 10 (10) 30 (8) .8
M4 Eo 17 (17) 26 (7) .08
M5 2 (2) 115 (30) <.01
M6 0 (0) 5 (1) 1.0
M7 0 (0) 44 (11) <.01
Unclassifiable/not known 5 (5) 15 (4) 1.0
FLT3 aberrations
Patients tested for FLT3
aberrations
73 311
ITD 0 (0) 42 (13) <.01
ALM (D835/I836) 2 (3) 8 (3) 1.0
Wild-type 71 (96) 261 (84) .5
Other molecular aberrations
Patients tested 59 185
NPM mutations 0 (0) 14 (8) <.01
CEBPa mutations 0 (0) 18 (10) <.01
Outcome
Dead during induction 3 (3) 10 (3) 1.0
Dead in CR after induction 4 (4) 33 (7) .5
Relapsed 24 (24) 79 (21) .7
Salvaged after relapse 17 (17) 13 (3) <.01
Dead during/after salvage
therapy
3 (3) 16 (4) 1
Dead after relapse 4 (4) 50 (13) .04
ALM, activating loop mutations; CEBPa, CCAAT/enhancer binding protein; ITD,
internal tandem duplication; NPM, nucleophosmin; Boldface P values denote
statistically significant differences (,.05).
Figure 3. Eight-year probability of OS and EFS for the whole cohort of 482
children enrolled in the AIEOP AML 2002/01 trial. FUP, follow-up.
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that special attention ought to be paid to the supportive therapy in
these categories of children. Previously published studies showed
that, also in acute lymphoblastic leukemia, adolescents are more
fragile than children.25-27 The reasons behind the observation that
adolescents have an increased risk for death in CCR are unclear, but
they may reflect age-dependent differences in immunologic response
to infections and tissue toxicity following chemotherapy.
The OS and EFS of our cohort of patients are comparable or
better than those reported by several other international cooperative
groups.5,6,24,28,29 Two recent reports have shown better results, since
the Japanese AML99 study reported a 5-year EFS and OS of 61% and
75%,8 respectively, and the AML02 single-center study from St. Jude
reported an EFS and OS at 3 years of 63% and 71%, respectively.7
However, it is noteworthy that the number of patients enrolled in
the AIEOP AML 2002/01 multicenter study is, together with that
reported by Gibson and coworkers,23 the highest of the published
protocols on childhood AML and that we report results at 8 years,
thus with a follow-up longer than that of St. Jude and Japanese
studies.7,8 Moreover, in our trial, neither patients with APL (enrolled
in the BFM trial)5 nor those with Down syndrome (enrolled in the
MRC trial) were included,6,30 and the proportion of patients with
CBF-b abnormalities is lower than that of the Japanese study (20% vs
37%, respectively).8
The risk stratification based on genetic features and response to
induction treatment, chosen in 2002 when the study was designed,
has confirmed its prognostic value also in our cohort. Indeed, HR
patients had both an OS and EFS probability worse than those of
SR patients. However, the difference was less pronounced for EFS
than for OS, since a higher proportion of SR patients than HR ones
can be rescued by second-line therapies (Table 3); this finding is in
line with a recent study reporting on the outcome of children with
relapsed AML.31 The outcome of our SR patients was inferior to
that reported by other groups.3,6-8,10,32 There is no obvious expla-
nation for this result. Considering compliance with dose intensity
as a possible reason for the outcome of our SR patients being
worse than expected, the median treatment duration for SR patients
was 170 days (range 135-210 days); the estimated median duration
of treatment of SR patients was 140 days. This delay could have
partly contributed to the unsatisfactory outcome of SR children.
The new AIEOP study will address the question of whether the use
of flow-cytometry–based minimal residual disease detection, which
is certainly much more sensitive than morphologic evaluation for
monitoring early leukemia clearance7 and/or early/repeated courses
of mitoxantrone,32 can improve the EFS of SR children.
The worse outcome observed in patients with monosomal karyo-
type has been reported in adult patients,33 but it is a relatively novel
observation for childhood AML, since only the negative impact of
monosomy 7 has been previously described.10,11,34 In the study by
Breems et al,33 out of 184 adults with monosomal karyotype, only
5 patients survived; similarly, in our study, only 2 out of 10 patients
are alive and disease-free. Taken together, these results indicate that
patients with monosomal karyotype should be considered at HR of
treatment failure and should be offered the most effective treatments
to prevent disease recurrence.
Figure 4. Eight-year probability of OS, EFS, DFS, and CI of relapse for SR and HR children enrolled in the AIEOP AML 2002/01 trial. (A) OS. (B) EFS. (C) DFS. (D) CI of REL.
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The outcome of children with WBC count at diagnosis
.100 3 109/L was significantly worse than that of patients with
lower counts, irrespective of their allocation to either the SR or the
HR group (data not shown). This finding is in line with previously
published reports,35 although more recent studies have documented
that repeated courses of intensive chemotherapy may abrogate the
impact on outcome of this variable.3,7
FLT3-ITD has been reported to be an adverse prognostic factor
in both adults and children with AML.36-38 The observation that our
42 patients with FLT3-ITD, 20 of them given ALLO-HSCT, had an
outcome not statistically different from that of HR patients without
this molecular abnormality can be explained considering that these
children, after 2006, were offered, if in CR and with an available
HLA-matched donor, ALLO-HSCT, a treatment associated with
an immune-mediated graft-versus-leukemia effect. Indeed, the DFS
of our children given ALLO-HSCT was 75% 1/2 15%. Previously
published studies have demonstrated that ALLO-HSCT can
supersede the negative prognostic impact of FLT3-ITD in AML.39,40
The broad use of either AUTO- or ALLO-HSCT in HR patients
resulted into a CI of leukemia recurrence superimposable to that of
SR children. This favorable effect of transplantation on the risk of
recurrence was not offset by an unacceptable CI of TRM. In this
regard, it is noteworthy that the outcome of ALLO-HSCT from
UD was similar to that of patients given HLA-compatible sibling
transplantation. This finding is backed by recent reports in patients
with acute lymphoblastic leukemia41,42 or nonmalignant disor-
ders43 and can be interpreted in view of optimization of HLA-
typing techniques and strategies for preventing or treating GVHD.
Children were given ALLO-HSCT in few experienced centers,
while a larger number of centers performed AUTO-HSCT; this
conceivably may have contributed to the comparable TRM ob-
served in AUTO- and ALLO-HSCT recipients. Support to the role
played by HSCT in preventing leukemia recurrence in our HR
patients is also given by the worse OS and DFS calculated by the
end of chemotherapy treatment observed in the 37 HR children
who were not transplanted at the end of consolidation therapy.
The DFS observed in our HR children given ALLO-HSCT is
comparable or better than that reported in other studies, which,
however, sometimes also included SR children.8,16,23,44,45 In view of
the remarkable chance of salvage recently reported in patients with
AML who experience relapse,31,46 transplantation could have been
spared in at least a proportion of our HR patients without jeopardizing
the probability of OS. This consideration has particular value in view
of the possible occurrence of late complications related to trans-
plantation, namely loss of fertility, endocrine disturbances, growth
impairment, and extensive chronic GVHD.47 The CI of this immune-
mediated complication in our cohort was 9% (SE 2.5).
In conclusion, in a large cohort of children with a long follow-up,
we show that risk-adapted therapy and broad use of HSCT resulted in
a significant improvement in the outcome as compared with previous
AIEOP protocols.4 The next AIEOP study will stratify patients into
3 risk groups, namely SR, HR, and very HR (VHR) children. The
former will include children with CBF-b anomalies as well as
cytogenetically normal, FLT3-ITD negative and nucleophosmin
mutated children with early MRD clearance, measured through flow
cytometry.7 In the VHR group, wewill allocate children with (1) poor
MRD clearance7; (2) WBC count at diagnosis .100 3 109/L in the
absence of molecular lesions typical of SR; (3) AML FAB-M7
without t(1;22); (4) complex or monosomal karyotype; (5) FLT3-
ITD; and (6) recently detected poor-prognosis molecular lesions.48,49
The remaining children will be assigned to the HR group. SR patients
will be offered chemotherapy-only treatment, while HR children with
an HLA-identical sibling available and all VHR children will be
offered an allograft. We will explore whether this refined strati-
fication permits us to further improve patient outcome and whether
EFS of HR patients without an HLA-identical sibling can be repro-
duced by substituting AUTO-HSCT with chemotherapy courses
including drugs such as fludarabine and amsacrine.
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Table 4. Probability of EFS by patient subgroup
Global population
No. of
patients
EFS %
(SE) P value
Risk stratification 482 55 (2.6)
SR 99 63 (5.6) .021
HR 383 53 (2.9) .021
Age
,1 y 63 58 (6.3) .91
1-2 y 52 58 (7.8) .91
2-10 y 181 55 (4.6) .91
.10 y 186 57 (4.0) .91
WBC count (3109/L)
,10 171 60 (4.4) .0001
10-99 236 57 (3.7) .0001
.100 75 37 (5.7) .0001
FAB types
M0 34 49 (8.9) .12
M1 88 44 (6.5) .12
M2 91 64 (5.8) .12
M4 83 64 (5.7) .12
M5 117 54 (5.6) .12
M6 5 100 (/) .12
M7 44 56 (7.7) .12
Unclassifiable/not known 20 41(14.5) .12
Subgroups
FLT3 Pos overall 52 47 (7,5)
FLT3-ITD Pos 42 47 (8.6)
FLT3-ALM (D835/I836) Pos 10 47 (6.7)
FLT3-ITD Pos vs FLT3-ITD Neg .22
11q23 abnormalities other than t(9;11) 46 52 (10.1)
11q23 abnormalities other than t(9;11) vs
other
.58
t(9;11) 19 61 (11.6)
t(9;11) vs other .78
Monosomal karyotype 10 20 (12.6)
Monosomal karyotype vs other karyotype .0002
Complex karyotype 27 40 (9.6)
Complex karyotype vs other karyotype .048
NPM mutations Pos 14 64 (15.2)
NPM Pos vs NPM Neg .24
CEBPa mutations Pos 18 60 (12.9)
CEBPa Pos vs Neg .33
ALM, activating loop mutations; CEBPa, CCAAT/enhancer binding protein; ITD,
internal tandem duplication; Neg, negative; NPM, nucleophosmin; Pos, positive;
Boldface P values denote statistically significant differences (,.05).
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